35541-25-4

Upstream product

• 81864-15-5 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride 
• 75-15-0 carbon disulfide 
• 38608-07-0 1,2-methylenedioxy-4,5-diaminobenzene 

Relevant academic research and scientific papers

Benzimidazole compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Synthesis, biological activity, QSAR and QSPR study of 2- aminobenzimidazole derivatives as potent H3-antagonists

We report the design, synthesis, QSPR and QSAR of a new class of H 3-antagonists, having a 2-aminobenzimidazole moiety connected to the 4(5) position of an imidazole ring through di- or tri-methylene chains. Eleven substituents, selected by experimental design to obtain broad and non-correlated variation in their lipophilic, electronic and steric properties, were introduced at the 5(6) position of the benzimidazole nucleus. The compounds were tested for their H3-receptor affinity, by displacement of [3H]-(R)-α-methylhistamine ([ 3H]-RAMHA) binding to rat brain membranes (pKi), for intrinsic activity, evaluating their effect on [35S]GTPγS binding to rat brain membranes, and for H3-antagonist potency, on electrically stimulated guinea-pig ileum (pKB). The pKi values of the derivatives with longer chain (5a-k) ranged over 2 orders of magnitude, with the 5(6)-methoxy derivative 5d endowed with sub-nanomolar affinity (pKi=9.37). The series having two methylene groups in the chain spacer (4a-k), showing a small variation in affinity, revealed to be somewhat insensitive to ring substitution. Lipophilicity (log P) and basicity (pKa) of the newly synthesized compounds were measured and related to receptor affinity in a QSAR study. Multiple regression analysis (MRA) showed an approximate parabolic dependence of pKi on log P, while an additional electronic effect of the substituents on benzimidazole tautomerism is suspected.

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.